KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill: 2022-2024

Historic Goodwill for Halozyme Therapeutics (HALO) over the last 3 years, with Dec 2024 value amounting to $416.8 million.

  • Halozyme Therapeutics' Goodwill changed negligibly% to $416.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.8 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $416.8 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Goodwill is $416.8 million, which was down 0.00% from $416.8 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Goodwill registered a high of $416.8 million during FY2023, and its lowest value of $409.0 million during FY2022.
  • For the 3-year period, Halozyme Therapeutics' Goodwill averaged around $414.2 million, with its median value being $416.8 million (2024).
  • Data for Halozyme Therapeutics' Goodwill shows a peak YoY rose of 1.90% (in 2023) over the last 5 years.
  • Halozyme Therapeutics' Goodwill (Yearly) stood at $409.0 million in 2022, then grew by 1.90% to $416.8 million in 2023, then remained steady at $416.8 million in 2024.